Daiichi Sankyo and ArQule announce top-line results of Phase 2 trial with tivantinib in colorectal cancer
15 January 2013 | By Daiichi Sankyo
“We are encouraged by these findings..."
List view / Grid view
News
Change to the Roche Corporate Executive Committee
15 January 2013 | By Roche
John C. Reed, M.D., Ph.D., has been appointed Head of Roche pRED and member of the enlarged Corporate Executive Committee...
New 1.3-micron Kinetex core-shell media delivers superior UHPLC performance
15 January 2013 | By Phenomenex
“The Kinetex product line spans our customers’ needs..."
Patient groups give Lundbeck top marks
14 January 2013 | By H. Lundbeck A/S
Lundbeck took first place in a global survey, in which 600 patient groups around the world evaluated the ability of 29 pharmaceutical companies to meet patient expectations...
Pivotal study in The Lancet shows potential of Novartis vaccine Bexsero® to help provide broad protection to infants against MenB
14 January 2013 | By Novartis
Findings from a pivotal Phase III clinical trial...
Regulatory update – GSK announces submission of albiglutide BLA to the US FDA for the treatment of type 2 diabetes
14 January 2013 | By GlaxoSmithKline
Albiglutide is not yet approved as a treatment for type 2 diabetes...
Thermo Fisher Scientific handheld instruments selected by USP for spectral library development project
Thermo Fisher Scientific Inc.,the world leader in serving science, announced that the United States Pharmacopeial Convention (USP) has selected its Thermo Scientific TruScan RM and microPHAZIR RX instruments to support its recent initiative to provide USP-approved libraries to pharmaceutical manufacturers.
Pfizer announces availability of Quillivant XR™ CII for extended-release oral suspension in the United States
14 January 2013 | By Pfizer
Quillivant XR™ CII for extended-release oral suspension is now available...
ZYTIGA® approved in the EU
11 January 2013 | By Johnson & Johnson
Janssen announced that the EC has approved an extension to the license of the oral, once-daily medication ZYTIGA®...
Merck provides update on next steps for TREDAPTIVE™ (extended-release niacin/laropiprant)
11 January 2013 | By Merck
Merck is taking steps to suspend the availability of TREDAPTIVE™ tablets worldwide...
Lundbeck appoints new vice president of global pricing and market access
11 January 2013 | By H. Lundbeck A/S
The move strengthens the company's capacity to bring drugs to market effectively...
Phase III data in The Lancet show significant benefit of Novartis drug Afinitor® in patients with non-cancerous tumors associated with TSC
11 January 2013 | By Novartis
Data published today...
Sirius Analytical product launch: surface dissolution imaging for real-time visualization of dissolution phenomena
10 January 2013 | By Sirius Analytical Instruments Ltd
Sirius Analytical Instruments Ltd announces the introduction of a new product...
Catalent makes major investment to expand inhalation capabilities in Research Triangle Park, NC
10 January 2013 | By Catalent Pharma Solutions
The investment will focus on expanding pMDI clinical and commercial supply capabilities...
New Abbott test available in Europe provides novel tool to aid doctors in evaluating potential heart attacks
An estimated 17 million people throughout the world die annually of cardiovascular diseases, specifically heart attacks or strokes.1 Time is a critical factor in diagnosing and treating people who may be having a potential heart attack. To aid physicians in detecting heart attacks sooner, Abbott announced today CE Marking (Conformité…
